메뉴 건너뛰기




Volumn 20, Issue 1, 2014, Pages 103-114

Patient preferences for surgical versus medical therapy for ulcerative colitis

Author keywords

DCE; IBD; Inflammatory bowel disease; Maximum acceptable risk

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TACROLIMUS;

EID: 84893639983     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000437498.14804.50     Document Type: Article
Times cited : (62)

References (41)
  • 1
    • 33847213152 scopus 로고    scopus 로고
    • A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis
    • Su C, Lewis JD, Goldberg B, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology. 2007;132:516-526.
    • (2007) Gastroenterology , vol.132 , pp. 516-526
    • Su, C.1    Lewis, J.D.2    Goldberg, B.3
  • 2
    • 84968747329 scopus 로고    scopus 로고
    • Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis
    • Timmer A,McDonald JW,Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;9:CD000478.
    • (2007) Cochrane Database Syst Rev , vol.9
    • Timmer, A.1    McDonald, J.W.2    Macdonald, J.K.3
  • 3
    • 28844473957 scopus 로고    scopus 로고
    • Infliximab for induction and maintenance therapy for ulcerative colitis
    • Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.
    • (2005) N Engl J Med , vol.353 , pp. 2462-2476
    • Rutgeerts, P.1    Sandborn, W.J.2    Feagan, B.G.3
  • 4
    • 41349088375 scopus 로고    scopus 로고
    • Risk factors for opportunistic infections in patients with inflammatory bowel disease
    • Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936.
    • (2008) Gastroenterology , vol.134 , pp. 929-936
    • Toruner, M.1    Loftus Jr., E.V.2    Harmsen, W.S.3
  • 5
    • 44949242296 scopus 로고    scopus 로고
    • Immunosuppressant medications and mortality in inflammatory bowel disease
    • quiz 1436
    • Lewis JD, Gelfand JM, Troxel AB, et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol. 2008; 103:1428-1435; quiz 1436.
    • (2008) Am J Gastroenterol , vol.103 , pp. 1428-1435
    • Lewis, J.D.1    Gelfand, J.M.2    Troxel, A.B.3
  • 6
    • 33646147141 scopus 로고    scopus 로고
    • Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry
    • Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630.
    • (2006) Clin Gastroenterol Hepatol , vol.4 , pp. 621-630
    • Lichtenstein, G.R.1    Feagan, B.G.2    Cohen, R.D.3
  • 7
    • 0347991877 scopus 로고    scopus 로고
    • The safety profile of infliximab in patients with Crohn's disease: The Mayo clinic experience in 500 patients
    • Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
    • (2004) Gastroenterology , vol.126 , pp. 19-31
    • Colombel, J.F.1    Loftus Jr., E.V.2    Tremaine, W.J.3
  • 8
    • 77950988234 scopus 로고    scopus 로고
    • Infliximab azathioprine or combination therapy for Crohn's disease
    • Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362: 1383-1395.
    • (2010) N Engl J Med , vol.362 , pp. 1383-1395
    • Colombel, J.F.1    Sandborn, W.J.2    Reinisch, W.3
  • 9
    • 67949112671 scopus 로고    scopus 로고
    • Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: A meta-analysis
    • Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874-881.
    • (2009) Clin Gastroenterol Hepatol , vol.7 , pp. 874-881
    • Siegel, C.A.1    Marden, S.M.2    Persing, S.M.3
  • 10
    • 22644446331 scopus 로고    scopus 로고
    • Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
    • Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121-1125.
    • (2005) Gut , vol.54 , pp. 1121-1125
    • Kandiel, A.1    Fraser, A.G.2    Korelitz, B.I.3
  • 11
    • 84855351626 scopus 로고    scopus 로고
    • The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006
    • Herrinton LJ, Liu L, Abramson O, et al. The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006. Pharmacoepidemiol Drug Saf. 2012;21:49-52.
    • (2012) Pharmacoepidemiol Drug Saf , vol.21 , pp. 49-52
    • Herrinton, L.J.1    Liu, L.2    Abramson, O.3
  • 12
    • 84872024555 scopus 로고    scopus 로고
    • T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: Results of the REFURBISH study
    • Deepak P, Sifuentes H, Sherid M, et al. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013; 108:99-105.
    • (2013) Am J Gastroenterol , vol.108 , pp. 99-105
    • Deepak, P.1    Sifuentes, H.2    Sherid, M.3
  • 13
    • 33748126607 scopus 로고    scopus 로고
    • Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis?
    • Arseneau KO, Sultan S, Provenzale DT, et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol. 2006;4:1135-1142.
    • (2006) Clin Gastroenterol Hepatol , vol.4 , pp. 1135-1142
    • Arseneau, K.O.1    Sultan, S.2    Provenzale, D.T.3
  • 14
    • 0000268935 scopus 로고    scopus 로고
    • Developments in non-expected utility theory: The hunt for a descriptive theory of choice under risk
    • Starmer C. Developments in non-expected utility theory: the hunt for a descriptive theory of choice under risk. J Econ Lit. 2000;38:332-382.
    • (2000) J Econ Lit , vol.38 , pp. 332-382
    • Starmer, C.1
  • 15
    • 34548490280 scopus 로고    scopus 로고
    • Crohn's disease patients' riskbenefit preferences: Serious adverse event risks versus treatment efficacy
    • Johnson FR, Ozdemir S, Mansfield C, et al. Crohn's disease patients' riskbenefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology. 2007;133:769-779.
    • (2007) Gastroenterology , vol.133 , pp. 769-779
    • Johnson, F.R.1    Ozdemir, S.2    Mansfield, C.3
  • 16
    • 58149191718 scopus 로고    scopus 로고
    • Are adult patients more tolerant of treatment risks than parents of juvenile patients?
    • Johnson FR, Ozdemir S, Mansfield C, et al. Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal. 2009;29:121-136.
    • (2009) Risk Anal , vol.29 , pp. 121-136
    • Johnson, F.R.1    Ozdemir, S.2    Mansfield, C.3
  • 17
    • 65749119370 scopus 로고    scopus 로고
    • Multiple sclerosis patients' benefit-risk preferences: Serious adverse event risks versus treatment efficacy
    • Johnson FR, Van Houtven G, Ozdemir S, et al. Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy. J Neurol. 2009;256:554-562.
    • (2009) J Neurol , vol.256 , pp. 554-562
    • Johnson, F.R.1    Van Houtven, G.2    Ozdemir, S.3
  • 18
    • 79959944619 scopus 로고    scopus 로고
    • Conjoint analysis applications in health - A checklist: A report of the ISPOR Good Research Practices for Conjoint Analysis Task Force
    • Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health-a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14:403-413.
    • (2011) Value Health , vol.14 , pp. 403-413
    • Bridges, J.F.1    Hauber, A.B.2    Marshall, D.3
  • 19
    • 0031812412 scopus 로고    scopus 로고
    • A simple clinical colitis activity index
    • Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29-32.
    • (1998) Gut , vol.43 , pp. 29-32
    • Walmsley, R.S.1    Ayres, R.C.2    Pounder, R.E.3
  • 20
    • 59849104111 scopus 로고    scopus 로고
    • Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis
    • Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660-1666.
    • (2008) Inflamm Bowel Dis , vol.14 , pp. 1660-1666
    • Lewis, J.D.1    Chuai, S.2    Nessel, L.3
  • 21
    • 0023521441 scopus 로고
    • Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study
    • Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
    • (1987) N Engl J Med , vol.317 , pp. 1625-1629
    • Schroeder, K.W.1    Tremaine, W.J.2    Ilstrup, D.M.3
  • 22
    • 84876390568 scopus 로고    scopus 로고
    • Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: A metaanalysis
    • Bewtra M, Kaiser L, TenHave T, et al. Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a metaanalysis. Inflamm Bowel Dis. 2013;19:599-613.
    • (2013) Inflamm Bowel Dis , vol.19 , pp. 599-613
    • Bewtra, M.1    Kaiser, L.2    Tenhave, T.3
  • 23
    • 0003432464 scopus 로고    scopus 로고
    • American Cancer Society. Accessed April 4, 2011
    • American Cancer Society. American Cancer Society. Available at: http://www.cancer.org/index. Accessed April 4, 2011.
    • American Cancer Society
  • 24
    • 0035995550 scopus 로고    scopus 로고
    • Optimal design for Multinomial choice experiments
    • Kanninen BJ. Optimal design for Multinomial choice experiments. J Marketing Res. 2002;39:214-227.
    • (2002) J Marketing Res , vol.39 , pp. 214-227
    • Kanninen, B.J.1
  • 27
    • 0030506691 scopus 로고    scopus 로고
    • The importance of utility Balance and Efficient choice designs
    • Huber J, Zwerina K. The importance of utility Balance and Efficient choice designs. J Marketing Res. 1996;33:307-317.
    • (1996) J Marketing Res , vol.33 , pp. 307-317
    • Huber, J.1    Zwerina, K.2
  • 31
    • 25144516913 scopus 로고    scopus 로고
    • Mixed logit with bounded distributions of correlated partworths
    • Alberini A, Scarpa R, eds., Dordrecht, The Netherlands: Springer Publisher
    • Train KE, Sonnier G. Mixed logit with bounded distributions of correlated partworths. In: Alberini A, Scarpa R, eds. Applications of Simulation Methods in Environmental and Resource Economics. Dordrecht, The Netherlands: Springer Publisher; 2005;117-134.
    • (2005) Applications of Simulation Methods in Environmental and Resource Economics , pp. 117-134
    • Train, K.E.1    Sonnier, G.2
  • 33
    • 79957618829 scopus 로고    scopus 로고
    • Eliciting benefit-risk preferences and probability-weighted utility using choice-format conjoint analysis
    • Van Houtven G, Johnson FR, Kilambi V, et al. Eliciting benefit-risk preferences and probability-weighted utility using choice-format conjoint analysis. Med Decis Making. 2011;31:469-480.
    • (2011) Med Decis Making , vol.31 , pp. 469-480
    • Van Houtven, G.1    Johnson, F.R.2    Kilambi, V.3
  • 34
    • 0023324565 scopus 로고
    • Perception of risk
    • Slovic P. Perception of risk. Science. 1987;236:280-285.
    • (1987) Science , vol.236 , pp. 280-285
    • Slovic, P.1
  • 35
    • 0026055338 scopus 로고
    • Quality of life of patients with ulcerative colitis preoperatively and postoperatively
    • McLeod RS, Churchill DN, Lock AM, et al. Quality of life of patients with ulcerative colitis preoperatively and postoperatively. Gastroenterology. 1991;101:1307-1313.
    • (1991) Gastroenterology , vol.101 , pp. 1307-1313
    • McLeod, R.S.1    Churchill, D.N.2    Lock, A.M.3
  • 36
    • 79953780408 scopus 로고    scopus 로고
    • Perceived and actual quality of life with ulcerative colitis: A comparison of medically and surgically treated patients
    • Waljee AK, Higgins PD, Waljee JF, et al. Perceived and actual quality of life with ulcerative colitis: a comparison of medically and surgically treated patients. Am J Gastroenterol. 2011;106:794-799.
    • (2011) Am J Gastroenterol , vol.106 , pp. 794-799
    • Waljee, A.K.1    Higgins, P.D.2    Waljee, J.F.3
  • 37
    • 79955866215 scopus 로고    scopus 로고
    • Individual health discount rate in patients with ulcerative colitis
    • Waljee AK, Morris AM, Waljee JF, et al. Individual health discount rate in patients with ulcerative colitis. Inflamm Bowel Dis. 2011;17: 1328-1332.
    • (2011) Inflamm Bowel Dis , vol.17 , pp. 1328-1332
    • Waljee, A.K.1    Morris, A.M.2    Waljee, J.F.3
  • 38
    • 84855185627 scopus 로고    scopus 로고
    • Proximity to disease and perception of utility: Physicians' vs patients' assessment of treatment options for ulcerative colitis
    • Brown LK, Waljee AK, Higgins PD, et al. Proximity to disease and perception of utility: physicians' vs patients' assessment of treatment options for ulcerative colitis. Dis Colon Rectum. 2011;54:1529-1536.
    • (2011) Dis Colon Rectum , vol.54 , pp. 1529-1536
    • Brown, L.K.1    Waljee, A.K.2    Higgins, P.D.3
  • 39
    • 84857051275 scopus 로고    scopus 로고
    • Shared decision making in inflammatory bowel disease: Helping patients understand the tradeoffs between treatment options
    • Siegel CA. Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. Gut. 2012;61:459-465.
    • (2012) Gut , vol.61 , pp. 459-465
    • Siegel, C.A.1
  • 40
    • 2942530847 scopus 로고    scopus 로고
    • Mesalamine derivatives in the treatment of Crohn's disease
    • ix-x
    • Harrell LE, Hanauer SB. Mesalamine derivatives in the treatment of Crohn's disease. Gastroenterol Clin North Am. 2004;33:303-317, ix-x.
    • (2004) Gastroenterol Clin North Am , vol.33 , pp. 303-317
    • Harrell, L.E.1    Hanauer, S.B.2
  • 41
    • 70649110836 scopus 로고    scopus 로고
    • Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis
    • Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009;137: 1934-1943.e1-3.
    • (2009) Gastroenterology , vol.137
    • Sandborn, W.J.1    Regula, J.2    Feagan, B.G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.